Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP
Jeffrey Fudin, PharmD, DAIPM, FCCP, FASHP
Dr. Jeff Fudin graduated from Albany College of Pharmacy & Health Sciences with a BS and PharmD. He is a Diplomate to the Academy of Integrative Pain Management, a Fellow to ACCP, ASHP, & FSMB, a member of several other professional organizations. He is CEO of Remitigate (remitigate.com), an opioid safety software development LLC. Dr. Fudin is a section editor for Pain Medicine & Co_Editor-A-Large for Practical Pain Management. He practices as a clinical pharmacy specialist (WOC) and director of PGY-2 pharmacy pain residency programs at the Stratton Veterans Administration Medical Center in Albany, New York and has academic affiliations with Western New England University and Albany Colleges of Pharmacy.
Articles
Nov 14, 2018 @06:41 PM
Millions worldwide dread the onset of debilitating migraines. There is a new drug class on the horizon that is thought to put a stop to the root of migraines. 

Oct 29, 2018 @04:00 PM
Despite a decline in the rate of opioid prescribing, the CDC reports that the number of opioid related deaths continues to rise. The pharmacology and pharmacokinetics of prescription and illicit fentanyl could help to shed light on why the opioid epidemic has taken the path that it has. 

Mar 6, 2018 @02:00 PM
Opioid allergies are often misdiagnosed. Improper allergy diagnosis may lead to delays in treatment and unnecessary drug avoidance. 

Feb 5, 2018 @07:56 AM
Although it is unclear what constitutes “unusual or disproportionate,” such phrases are particularly disturbing when we realize that the regulation of medical practice is a traditional state function, not a federal one.

Jan 6, 2018 @01:00 PM
A look at the different receptor bindings that affect analgesic effect.

Dec 20, 2017 @03:09 AM
The established therapeutic dosing for gabapentin in neuropathic pain is 1800-3600 mg/day in 3 divided doses in patients with normal renal function.

Oct 18, 2017 @08:05 AM
Here is how to distinguish between those who need prescriptions to manage pain and those seeking controlled substances for illicit reasons.

Aug 24, 2017 @04:21 AM
This testing has a positive clinical and therapeutic impact on dosage requirements and ethical considerations.

Feb 27, 2017 @04:51 AM
Prescribers and pharmacists in various clinical roles are often challenged when treating patients with comorbid chronic pain and end-stage renal disease (ESRD) or hemodialysis (HD). There is a dearth of clinical guidelines available for chronic pain management in this setting. Those selecting pharmacotherapy for patients must rely on clinical judgement, literature analysis and prudent decision making.

Dec 15, 2016 @09:19 AM
A recent New England Journal of Medicine publication addressed the rising costs of naloxone, but failed to address many of the hidden issue that are buried within routine pharmacy practice. Here we unveil some of the less obvious reasons and offer software solutions to help pharmacists safe lives.

Nov 17, 2016 @03:29 AM
Buprenorphine is one of the most commonly prescribed medications to treat opioid addiction. In 2014, about 60-65% of Americans using medication-assisted treatment received buprenorphine. On July 6, 2016, the Department of Health and Human Services (HHS) announced that it will raise the limit on the number of patients that can receive the addiction medicine buprenorphine to 275 patients per qualified provider. This article describes potential monetary conflicts in proving buprenorphine, how increased access will affect pharmacists and what they can do to help patients in need of medication supported abstinence and substance abuse counseling.

Jun 28, 2016 @06:50 AM
Pharmacists in all health care settings commonly see what seems like lifelong refills for cyclobenzaprine for musculoskeletal conditions.

May 19, 2016 @05:31 AM
Pharmacists are in a unique position to assess patients' risks and then qualify them for specific opioids.

Mar 22, 2016 @07:03 AM
Buprenorphine is now available in several dosage forms with various indications.

Dec 18, 2015 @08:45 AM
Deaths from unintentional opioid overdose have increased 56% since 2010.

Sep 29, 2015 @02:01 AM
Opioid-induced androgen deficiency is a common yet underdiagnosed adverse effect of chronic opioid use.

Sep 22, 2015 @02:27 AM
Pregabalin and gabapentin are often considered first-line treatments for various neuropathic pain syndromes, generally irrespective of cause

Sep 16, 2015 @05:32 AM
While NSAIDs are effective in treating various pain conditions, their long-term risks frequently preclude safe chronic use in many patients.

Sep 9, 2015 @03:44 AM
Treating chronic noncancer pain with long-term opioid use is a challenging task for all health care providers.

Sep 1, 2015 @02:26 AM
Community pharmacists have the opportunity to identify patients at risk for opioid overdose.

Aug 24, 2015 @01:18 AM
Monoclonal antibodies are a relatively new class of biologic agents.

Jul 16, 2015 @09:50 AM
Is there a need to strengthen the labeling of topical NSAIDs that clearly lack systemic therapeutic or toxic levels?

May 5, 2015 @09:54 AM
Monitoring and evaluating the therapeutic relevance of drug interactions is an important mission for any practicing pharmacist.

Apr 2, 2015 @02:23 AM
Targeted counseling for patients taking zolpidem (Ambien) might be synonymous with saving lives.

Jan 27, 2015 @04:36 AM
While extended-release opioid analgesics are an essential component of pain management, abuse and misuse of these medications can cause substantial morbidity and mortality.

Oct 24, 2014 @01:08 AM
It is compulsory for pharmacists to counsel all patients receiving opioids, evaluate the potential benefit of a naloxone reversal device, and contact the opioid prescriber if such a device is deemed appropriate.

Oct 6, 2014 @12:02 PM
In response to the recent article by Gary M. Franklin, MD, MPH, titled "Opioids for chronic non-cancer pain: A position paper of the American Academy of Neurology," we wish to address a number of issues.

Sep 24, 2014 @04:03 AM
'The Holy Trinity' is a drug regimen that includes at least an opioid, a benzodiazepine, and carisoprodol.